Live Breaking News & Updates on University Of Michigan Cancer
Stay updated with breaking news from University of michigan cancer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Share this article Share this article COPENHAGEN, Denmark, May 25, 2021 /PRNewswire/ IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced today the appointment of Muhammad Al-Hajj, PhD as Chief Scientific Officer. He will report to the CEO and be based in the Washington DC metro area, United States, where the company will establish an R&D site. Dr. Muhammad Al-Hajj We are thrilled that Dr. Al-Hajj is joining IO Biotech at such an exciting time in the development of our company, said Mai-Britt Zocca, PhD, Chief Executive Officer, and founder of IO Biotech. He is a well-respected scientific leader with deep expertise and a proven track record in the field of immuno-oncology with expertise in translational medicine and biomarker discovery. Dr. Al-Hajj will play a pivotal role in harnessing the power of our T-win technology platform to build on ....